CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Yahoo Finance Published Updated Stocks
Sign in to save

Affected assets and topics

SHARES MARKET TRADING NASDAQ

Why it matters

CERo Therapeutics has announced that its shares will be suspended from trading on Nasdaq starting October 31, following a panel determination. The company plans to appeal this decision and seek trading on OTC Markets while continuing its clinical operations.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bearish Confidence 85% How confidence is read Impact: Moderate

Market impact analysis based on bearish sentiment with 85% confidence.

Evidence trail

Evidence
Source Yahoo Finance
Claim CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
AI inference Bearish · 85%
Generated 2025-10-29 23:22

AI provenance

Analysed by GPT 4o Mini (OpenAI) Methodology v1.0 Generated
Technical identifiers
Provider tag
openai-gpt-4o-mini
Analysis version
openai-gpt-4o-mini
Article id
4376

Original source

Trading of the Company’s shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue clinical operations SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, to

Read the full article on Yahoo Finance

Original article published by Yahoo Finance on October 30, 2025. Analysis and insights provided by AnalystMarkets AI.

Related coverage